PROVE-HF Biomarker Improvement Algorithm (PROVE-HF Calculator)
Biomarker change assessment
Compare NT-proBNP at baseline and follow-up. Enter LVEF at baseline for clinical context; this tool does not predict an individual follow-up LVEF.
About PROVE-HF
PROVE-HF was a prospective, open-label, single-arm study that evaluated associations between changes in NT-proBNP after initiation of sacubitril/valsartan and changes in cardiac structure and function in patients with heart failure with reduced ejection fraction.
Among 794 enrolled participants, median NT-proBNP decreased from 816 pg/mL at baseline to 455 pg/mL at 12 months. Mean LVEF increased from 28.2% to 37.8%, an absolute increase of 9.4 percentage points. The change in log₂ NT-proBNP correlated with change in LVEF (r = −0.381).
How this calculator works
- Percentage change = [(follow-up − baseline) ÷ baseline] × 100.
- Absolute change = follow-up − baseline, in pg/mL.
- Ratio = follow-up ÷ baseline.
- Log₂ fold change = log₂(follow-up ÷ baseline).
Interpretation and limitations
A fall in NT-proBNP can be consistent with improvement, but must be interpreted alongside symptoms, signs, renal function, rhythm, volume status, treatment, and measurement timing. The study was single-arm and its correlations were not designed as a calibrated individual prediction model. This calculator therefore does not estimate LVEF change, mortality, or treatment benefit.
Reference
Study registration: ClinicalTrials.gov NCT02887183.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.